New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/16/suppl_2/ii191/379510/mdi719.pdf
Reference43 articles.
1. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women;Fossati;J Clin Oncol,1998
2. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens;A’Hern;Br J Cancer,1993
3. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer;Rahman;J Clin Oncol,1997
4. Combined modality approach for patients with isolated recurrences of breast cancer (IV NED);Holmes;The MD Anderson experience. Breast Dis,1994
5. Fluorouracil, doxorubicin, and cyclophsphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease;Rivera;Breast J,2002
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The Effect of Nano Albumin Combined with Paclitaxel on Drug Resistance of Breast Cancer Through Regulating ATP Binding Cassette Subfamily B Member 1 (ABCB1);Journal of Biomaterials and Tissue Engineering;2022-05-01
2. GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer;Oncotarget;2017-11-14
3. Efficacy and Safety of Nedaplatin in Advanced Breast Cancer Therapy;Cancer Investigation;2016-04-08
4. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials;Tumor Biology;2014-11-12
5. The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials;Tumor Biology;2014-02-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3